According to this study, PRGs risk models were defined with the combination of immune and signaling pathways genes (CASP4, GSDMC, NLRP1, PLCG1, IL-18, CASP1, and NLRP2), among which CASP4, NLRP1, PLCG1, IL-18, and CASP1 are overexpressed in pancreatic cancers. The gene discussed is PLCG1; the disease is familial pancreatic carcinoma.